08:50 EDT Omeros (OMER) up 124% at $9.20 after entering license agreement for zaltenibert
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH
- Promising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy Rating
- Omeros announces publication of narsoplimab survival outcomes in TA-TMA
- Omeros Corporation’s Positive Earnings Call Highlights Progress